Introduction
D4T has been referred to by a number of names, including 2 1 ,3'-dideoxy-2' ,3 /-didehydrothymidine, 2 /,3'-didehydro-3'-deoxythymidine, dldeoxythyrnidin-Z'<ene, and 1-(2,3-dideoxY-I3-D-glycero-pent-2-enofuranosyl)thymine. Stavudine is the name adopted by the USAN council.
D4T is a structural analogue of the naturally occurring nucleoside thymidine. The structure of D4T is shown in Fig. 1 , along with thymidine and the anti-HIV drug, 3'-azido-3'-deoxythymidine (AZT). The synthesis of D4T was first described by Horwitz et al. (1966) but no biological activity was reported. The discovery of activity of D4T against a mouse retrovirus (Lin et al., 1987a) resurrected interest in it as a potential anti-human immunodeficiency virus (HIV) agent because the activity of other dideoxynucleosides, e.g. AZT, dideoxycytidine (ddC) and dideoxyinosine (ddl), was known. Extended biological evaluation was facilitated by the development of a scaled-up synthesis capable of producing D4T in 50-g lots (Mansuri et al., 1989) .
In vitro activity

Activity against HIV
A number of laboratories have detailed the activity of D4T against HIV-1 in vitro (fable 1). In most studies, the potency of D4T was similar to AZT in spite of significant differences in assay methodology. The exception is the data from Inoue et al. (1989) , which shows 100-fold less activity for D4T. The anticellular activity of the two compounds is also similar (within threefold). Schreiber and Ikemoto (1988) have also reported that D4T has activity comparable to AZT against the RF strain of HIV-1 in 8166 cells. D4T was equally active against HIV-2 and HIV-1 
Cytotoxicity to bone marrow progenitor cells
In order to assess in vitro the potential for toxicity against bone marrow progenitor cells in humans, 04T has been compared to AZT in colony-forming assays of human or murine bone marrow (Table 3 ).-The results from different authors are somewhat at variance. In some studies, with human granulocyte/monocyte progenitors, 04T was 20-100-fbld less toxic than AZT. In other-studies and with other cells, the differences found were much less striking.
Mechanism of action
Metabolism of D4T to the triphosphate in cells
The metabolism of labelled 04T has been the subject of several studies using H9 , CEM (Ho   AZT  Thymidine and Hitchcock, 1989a), MT-4 cells (Balzarini et al., 1989a) or human peripheral blood mononuclear cells (PBMC) stimulated with phytohaemagglutinin (Zhu et aI., 1990) or monocyte/macrophages (Perno et aI., 1989) : In all these cells, 04T is activated to the mono-, dl-and tri-phosphate. In contrast to AZT metabolism, where the major phosphorylated metabolite is the monophosphate (Furman et al., 1986; Ho and Hitchcock, 1989a; Balzarini et al., 1989a) , 04T monophosphate does not accumulate and the ratio of mono-to dl-to triphosphate is relatively constant (between 1 : 1 :1 and 1: 1 :3, depending on the study). By contrast, in quiescent human peripheral blood mononuclear cells, neither 04T nor AZT are measurably phosphorylated (Ho"and Hitchcock, 1989b; Zhu et aI., 1990) , probably because "thymidine kinase is not expressed under these conditions. Baba et al. (1987) . b. Hamamoto et al. (1987) .
c. Balzarini et al. (1987) ; Herdewijn et al. (1987) .
d. Mansuri et al. (1989) .
e.lnoue et al. (1989) . f. Lin et al. (1987b); Chu et al. (1989) .
g. Monocyte/macrophage with HTLV-IIIB; Perno et al. (1989) .
h. Monocyte/macrophage with HTLV-IIIBa_ L ; Perno et al. (1989) .
l, Balzarini et al. (1989b) . TI, therapeutic index (In vitro) = 10 50 for celis/10 50 for virus. Ho and Hitchcock (1989a) ; (0) (pmol/1 0 6 cells) Balzarini et al. (1989a) ; (f',) (pmol/10 6 cells) Martin et al. (1990) .
plasma fall quite quickly to undetectable levels. In GEM cells, the 04T triphosphate pool decays with a half-life of about 3.5h (Ho and Hitchcock, 1989a) . Under similar conditions the half-life of AZT triphosphate was the same. Similar experiments in human PBMG also show a half-life of 3.5 h for 04T triphosphate (Zhu et aI., 1990) .The length of the intracellular half-life of the triphosphate, coupled with the dose proportionality of triphosphate formation in cells, provided a rationale for exploring b.i.d, and t.l.d. dosing schedules in patients.
Most of the accumulated evidence points to thymidine kinase being the enzyme responsible for activation of 04T to the monophosphate. Thymidine (but not dideoxyadenosine, dideoxyinosine or deoxycytidine) added to the growth medium completely suppresses phosphorylation (Ho and Hitchcock, 1989a; Balzarini et al., 1989a) .Thymidine also inhibits the antiviral activity of 04T (Balzarini et al., 1989a) . Since thymidine is phosphorylated by thymidine kinase (TK), the result also implicates this enzyme as responsible for phosphorylation of 04T. One discrepancy is the claim that a TK-negative mutant human cell line (RajifTK-) phosphorylates 04T and allows expression of anti-HIV activity (Balzarini et aI., 1989a) . However, an alternative explanation is that the mutated TK protein retains the ability to phosphorylate 04T but not thymidine or AZT. Ho and Hitchcock (1989b) showed that 04T and AZT are phosphorylated by TK+ mouse cells (L1210) but not by a TK-mutant mouse cell line (LMTK-).
Inhibition by 04T ofthymidine kinase purified from GEM cells was reported (Ho and Hitchcock, 1989a) . The inhibition constant {}Q for 04T was 4600 J.LM compared with a Michaelis constant (Kml of 7 J.LM for thymidine. This Contrasts with AZT, which had a~of 7.6J.LM under these conditions. Furman et al. (1986) have also presented evidence that AZT and thymidine are recognized by thymidine kinase from H9 cells in an essentially identical way, with K m and~values for both being in the range of 2-3 J.LM. Marongiu et al. (1990) have also shown that 04T 125 0,5 0.5
The production of phosphorylated intracellular 04T metabolites shows a fairly good dose-response with respect to the extracellular concentration of the drug (Fig.  2) . The concentration of 04T triphosphate in GEM cells increased by 100-fold for a 400-fold increase in extracellular 04T concentration (up to 20 J.LM). By contrast, AZT triphosphate concentration showed a poor doseresponse and was increased only fourfold for a 1000-fold increase in AZT concentration. Similar effects have been described in GEM cells using higher extracellular concentrations of the two compounds (Martin et al., 1991) . Oifferences in dose-responses for the two compounds were also shown with MT-4 cells (Balzarini et al., 1989a) . These findings indicate that the intracellular concentrations of the active species can be more easily and predictably controlled with 04T than with AZT by modulation of the exposure, and this may lead to better predictability of clinical effects.
Since the triphosphate is believed to be the metabolite active against HIV (vide infra), measurement of its persistence in cells after removal of free drug from the medium is important. This creates a situation analogous to that seen after dosing animals where free drug concentrations in Mouse Human a. Sommadossi et al. (1990) ; Mansuri et al. (1989) . b. Mansuri et al. (1990) . c. Inoue et al. (1989) . d. Gogu et al. (1989) . CFU, colony-forming units; BFU, burst-forming units; G, granulocyte; M, monocyte; E, erythroid.
Organism
Staphylococcus aureus Escherichia coli Salmonella enteritidis Proteus mirabilis
Pseudomonas aeruginosa has a high K; (1370J-LM) with respect to thymidine phosphorylation for thymidine kinase from H9 cells. These authors also reported its utilization as a substate for this enzyme (K m = 138 J-LM). This has been confirmed in our studies using TK from CEM cells (M. J. M. Hitchcock, unpublished data), but with a higher K m of 1600 J-LM. This high value does not necessarily argue for the involvement of another enzyme, but merely indicates that the rate of phosphorylation and equilibration will not be rapid.
04T has little effect on metabolism of exogenously labelled thymidine (Mansuri et aI., 1989) . By contrast, AZT blocks phosphorylation of thymidine to the diphosphate. This is seen as an increase in labelled TMP and a decrease in labelled thymidine diphosphate (TOP) and thymidine triphosphate (TTP). The lack of peturbation of labelled thymidine nucleotides by 04T suggests that this compound does not modulate production of TIP, and thus synthesis of normal host ONAshould not be inhibited. Furman et al. (1986) also described an 18-fold suppression of TIP levels by AZT in H9 cells, but subsequent studies in H9 and two other human cell lines (HL-60 and K-562) suggested that the suppression was limited and transient (Frick et aI., 1988) .
Orug interaction experiments using labelled 04T with unlabelled AZT or vice versa (Ho and Hitchcock, 1989a) show that AZT inhibits phosphorylation of D4T: only 50%, 6% and 3%, respectively, of control levels of mono-, diand tri-phosphates were found. By contrast,' 04T has no effect on phosphorylation of AZT. These results, and the effects on thymidine metabolism described above, are consistent with the hypothesis that one enzyme is responsible for activation of both drugs (thymidine kinase) and 
"y e that it has a much higher affinity for AZT than 04T. The results also caution against combination of these two agents since AZTwili prevent 04T from producing triphosphate and thus exerting an antiviral effect.
Inhibition by D4T triphosphate of reverse transcriptase (RT) and other DNA polymerases
The inhibitory effects of 04T and AZT triphosphates on HIV-RT is shown in Table 4 . For comparison, results with other ONApolymerases are also included. In spite of some variability of the data from the different reports, it is clear that 04T-TP is a very effective inhibitor of the viral enzyme because it has a binding constant lower than that for the natural substrate, TIP. In general, its potency is similar to that of AZT-TP against RT from HIV and FIV. However, with the RT from MuLV, it is about eightfold less potent than AZT-TP. With reverse transcriptase from different sources (avian myeloblastosis virus and Rous Sarcoma virus) it has been shown that 04T-TP can terminate ONA chain elongation by being incorporated at sites normally occupied by thymidine (Oyatkina et al., 1987) . This mechanism has also been described for AZT-TP using Escherichia coli Klenow fragment (Elwell et aI., 1987) and using reverse transcriptase from Moloney murine leukaemia virus and HIV (St Clair et al., 1987) . Both the inhibition and incorporation aspects can impact on the antiviral effect by reducing the production of full length double-stranded DNA, an event in the retrovirus replication cycle needed prior to integration of the virus into the host genome. b. Mansuri et al. (1990). c. North et al. (1990) .
d. Matthes et al. (1987). e. Ono et al. (1989) .
f. Results are 1050, not 1<;. NI, not inhibitory; 81, slightly inhibitory.
Cellular DNA polymerases have also been studied with triphosphates of D4T and AZT (Table 4 ). In one study, a-polymerase was not inhibited at very high concentrations of either compound (>200 I-LM). However, Ono et al. (1989) showed that substitution of Mg 2 + in the assay with Mn 2 + allows inhibition to be seen with D4T-TP. Dyatkina et al. (1987) , using oligonucleotide primer extension assays, have shown inhibition can be observed using 500 I-LM D4T-TP and 10I-LM TIP with a-polymerase. Even under these conditions though, D4T does not appear to be irreversibly incorporated since addition of more TIP results in further extension of the DNA fragments. (3-polymerase is inhibited by both D4T-TP andAZT-TP. Matthes et al. (1987) find D4T-TP to be 3D-fold more potent than AZT-TP against the (3-polymerase, and Ono et al. (1989) also find D4T-TP to be more inhibitory to this enzyme. It has been claimed (Dyatkina et al., 1987) that with (3-polymerase, D4T-TP is incorporated into DNA and terminates chain extension. There was no dose-effect, however, since no difference in termination fragments was seen at a range of D4T-TP concentrations covering two orders of magnitude. 'V-Polymeraseis very sensitive to inhibition by D4T-TP, and the K; is 3D-fold lower than that for AZT-TP. The development of peripheral neuropathy in patients dosed with dideoxynucleosides (see below) might be related to the interaction of their triphosphates with v-polymerase (Starnes and Cheng, 1987) causing mitochondrial depletion (Chen and Cheng, 1989) . In contrast to the result with 'V-polymerase, D4T had only a small effect on incorporation of labelled precursors into DNA in isolated rat mitochondria (Simpson et aI., 1989) . Inhibition by AZT was greater than for D4T in this system, especially when [3Hjthymidine was used.
Pharmacokinetics and metabolism in vivo
D4T has been shown to be stable at low pH (pH 2, Ghazzouli et al., 1988; pH 1.0, Kawaguchi et aI., 1989) . This property encouraged the exploration of oral bio-availability.ln mice, oral bio-availabilitywas 98% (Russellet al., 1990) and the highest concentration in plasma was at 5 min (the first time of sampling). Thus, in mice, D4T is rapidly and completely absorbed when given by the oral route. In monkeys (Schinazi et al., 1990) , oral bio-availability of D4T was reported to be 42% and subcutaneous bio-availability ranged from 59% to 77%. Serum half life was between 0.8 and 1.4h. Kaul et al. (1989) has also reported high plasma concentrations of D4T in rat (200I-Lg/ ml) and monkey (300I-Lg/ml) dosed orally with 200 and 300 mg/kg D4T, respectively. Half-lives were about 0.5-0.8 h for these high doses.
Concentrations of D4T in the brain increase to 0.8 I-Lg/g of tissue (-31-LM) after a 25 mg/kg oral dose in mice, and then stay constant up to 60 min (Russell et aI., 1990) . In Antiviral portraits: anti-HIV D4T 129 monkeys, the ratio of concentrations of D4T in cerebrospinal fluid to s-erum measured 1 h after dosing was 0.15 (Schinazi et el., 1990) . This ability of anti-HIV drugs to penetrate the blood-brain barrier is considered important for the treatment of aquired immunodeficiency syndrome (AIDS) dementia.
Urinary excretion of unchanged drug over 24 h was 74%, 78% and 51% for the rat, dog, and monkey, respectively (Russell et et., 1990) . High-pressure liquid chromatography (HPLG) analysis of urine after administration of 14C-D4Tshowed that essentially all the radioactivity recovered was present as D4T, and treatment of the urine with glucuronidase did not change the HPLC profile. It was concluded that D4T was not glucuronidated in any species, unlike AZT which is subject to extensive glucuronidation in monkey as well as in man (Collins and Unadkat, 1989) . By contrast, Schinazi et al. (1990) suggested D4T glucuronide was formed to a small extent in the monkey. However, its presence was only inferred by comparisons of nucleoside concentrations before and after incubation with glucuronidase, and direct measurement of glucuronide was not performed.
Toxicology
A 3D-day mouse toxicity study has been reported (Mansuri et el., 1990) . D4T was administered orally at doses of 100, 250, 500, and 1000 mg/kg/day and AZT was compared as a reference agent. Major haematological toxicities (anaemia, neutropaenia and Iymphopaenia) were associated with AZT but not with D4T. The dose-limiting toxicity for D4T in mice was hepatotoxicity based on elevated serum alanine aminotransferase and gross or microscopic liver changes in some mice given 500 or 1000 mg/kg/day. In rats, the liver is also the organ most consistently affected by D4T. D4T at daily oral doses of 500 to 1000 mg/kg given for t-week, 1-month or 3-months was associated with enlarged livers and hepatocellular hypertrophy in some rats (Bristol-Myers Squibb, data on file).
Clinical evaluation
A pharmacokinetic study has been described in groups of five patients with AIDS or AIDS-related complex dosed orally on a q.i.d. regimen with 0.5, 1 or 2 mg/kg (S. Kaul et al., Abstract S.B.455, VI International Conference on AIDS, San Francisco, 1990) . T max was less than 1 hand C max was dose-related (Table 5 ). Pharmacokinetics at steady state (Day 8, 9 or 20) were consistent with those for a single dose. Bio-availability in humans was about 86% (compared with 65% for AZl) and the area under the curve (AUG) was about fourfold greater than that seen with AZT for a comparable dose (Martin et aI., 1990) .The absence of Beneficial responses were seen in the majority of patients. In one study, of nine patients with measurable serum p24 antigen, p24 became undetectable in eight patients within 2-5 weeks of therapy, including those patients dosed with 2mg/kg/day (K. E. Squires et aI., AbstractThA 241).When therapy was interrupted, serum p24 antigen levels rose rapidly to high levels, but were again suppressed by restarting therapy. In another study, with 10 patients which were positive for p24 antigen, five became negative and five showed a decline in level (M. J.
Browne et aI., Abstract S.B. 456). Other surrogate markers for HIV disease progression (sustained increases in CD4 cells and weight gain) were also improved. Further studies designed to assessthe effects of lower doses are ongoing.
Conclusion
D4T has in vitro activity against HIV and toxicity to cells in culture almost comparable to that of AZT. However, in some assays with human bone marrow progenitor cells (granulocyte/monocyte lineage) D4T has significantly less toxicity than AZT.
As has been shown with AZT, the nucleoside triphosphate is the active intracellular species and D4T triphosphate inhibits HIVreversetranscriptase by competing with the natural substrate, TIP. Reported binding constants (K;) are low (about 1OO-fold) compared with the K m for TIP, and similar to those measured for AZT triphosphate. Since the mechanism involves competing with the natural substrate TIP, the efficacy of inhibition in vivo will be likely to be dependent on the intracellular concentrations of both of the triphosphates. (As described earlier, D4T does not suppress TIP whereas AZT may.) These triphosphates also serve as chain-terminating substrates for reverse transcriptase, causing irreversible inhibition of DNA synthesis. With mammalian polymerases (except 'Y-polymerase), much higher concentrations of the triphosphates are needed to inhibit DNA synthesis, and the inhibition may be reversible. Selectivity is presumably achieved from these differential effects on host and viral enzymes. As a result of its different affinities for different enzymes, the cellular pharmacology of D4T is different from AZT. In particular, the concentration of the antiviral species, the triphosphate, has a much better dose-response to the extracellular concentration of free drug with D4T than with AZT, and D4T rnonophosphate does not accumulate. The ability to use the 3.5~intracellular half-life of D4T triphosphate to support dosing frequencies of only two to three times per dayls dependent on this dose-response, since the AUC of the triphosphate for each dose should be doubled by giving twice the dose at half the frequency.
In animals and humans, the oral bio-availability of D4T is consistent and relatively high (>80%), and no significant metabolites have been detected. Although the plasma half-life of the free drug is short, this may not be relevant to the dosing strategy (seeabove). The dose-limiting toxicity in humans is peripheral neuropathy, which was not predicted by animal toxicology. Peripheral neuropathy is also the most common dose-limiting toxicity associated with ddl or ddC therapy, and may be a class effect related to inhibition of DNA 'Y-polymerase. Favourable changes in the surrogate markers of HIV disease progression (p24 antigenaemia, CD4 numbers and weight gain) have been seen in a limited number of patients treated with D4T; however, the doses explored to date have produced side-effects (usually neuropathy) in a few cases after prolonged administration. Thus further clinical studies to evaluate the safety and efficacy of lower doses are currently ongoing.
